Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 437, Issue 3, 2013, Pages 463-468

  Jin, Hyeon Ok ^a   Lee, Yun Han ^b   Kim, Hyun Ah ^a   Kim, Eun Kyu ^a   Noh, Woo Chul ^a   Kim, Young Sun ^c   Hwang, Chang Sun ^c   Kim, Jong Il ^d   Chang, Yoon Hwan ^e   Hong, Seok Il ^e   Hong, Young Jun ^e   Park, In Chul ^a   Lee, Jin Kyung ^a,e  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Catholic Kwandong University   (South Korea)

^d Seoul Women University   (South Korea)

^e KOR Cancer Center Hospital   (South Korea)

Author keywords

Breast cancer; CHOP; Estrogen receptor; HER2; Tamoxifen; Vacuolar H+ ATPase

Indexed keywords

ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; PROTEOLIPID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; VACUOLAR PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

BREAST CANCER; CHOP; ESTROGEN RECEPTOR; HER2; TAMOXIFEN; VACUOLAR H+ ATPASE;

APOPTOSIS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; TAMOXIFEN; TRANSCRIPTION FACTOR CHOP; UP-REGULATION; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84880945595     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.106     Document Type: Article

References (28)

1. Youlden D.R., Cramb S.M., Dunn N.A., Muller J.M., Pyke C.M., Baade P.D. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36:237-248.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2008, 127(2010):2893-2917.
3. Colleoni M., Bagnardi V., Rotmensz N., Gelber R.D., Viale G., Pruneri G., Veronesi P., Torrisi R., Cardillo A., Montagna E., Campagnoli E., Luini A., Intra M., Galimberti V., Scarano E., Peruzzotti G., Goldhirsch A. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res. Treat. 2009, 116:359-369.
4. Regan M.M., Viale G., Mastropasqua M.G., Maiorano E., Golouh R., Carbone A., Brown B., Suurkula M., Langman G., Mazzucchelli L., Braye S., Grigolato P., Gelber R.D., Castiglione-Gertsch M., Price K.N., Coates A.S., Goldhirsch A., Gusterson B. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl. Cancer Inst. 2006, 98:1571-1581.
5. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., Dowsett M., Ingle J., Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
6. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol. 2007, 8:917-929.
7. Nishi T., Forgac M. The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat. Rev. Mol. Cell Biol. 2002, 3:94-103.
8. Gu F., Gruenberg J. ARF1 regulates pH-dependent COP functions in the early endocytic pathway. J. Biol. Chem. 2000, 275:8154-8160.
9. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
10. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 2008, 49(Suppl. 2):24S-42S.
11. López-Lázaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?. Anticancer Agents Med. Chem. 2008, 8:305-312.
12. Torigoe T., Izumi H., Ise T., Murakami T., Uramoto H., Ishiguchi H., Yoshida Y., Tanabe M., Nomoto M., Kohno K. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 2002, 13:237-243.
13. Bowman E.J., Graham L.A., Stevens T.H., Bowman B.J. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from neurospora crassa and Saccharomyces cerevisiae. J. Biol. Chem. 2004, 279:33131-33138.
14. Hong J., Nakano Y., Yokomakura A., Ishihara K., Kim S., Kang Y.S., Ohuchi K. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7. J. Pharmacol. Exp. Ther. 2006, 319:672-681.
15. Choi H.N., Jin H.O., Kim J.H., Hong S.E., Kim H.A., Kim E.K., Lee J.K., Park I.C., Noh W.C. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2013, 432:123-128.
16. Lim J.H., Park J.W., Kim S.J., Kim M.S., Park S.K., Johnson R.S., Chun Y.S. ATP6V0C competes with von Hippel-Lindau protein in hypoxia-inducible factor 1alpha (HIF-1alpha) binding and mediates HIF-1alpha expression by bafilomycin A1. Mol. Pharmacol. 2007, 71:942-948.
17. Kim Y.S., Jin H.O., Seo S.K., Woo S.H., Choe T.B., An S., Hong S.I., Lee S.J., Lee K.H., Park I.C. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem. Pharmacol. 2011, 82:216-226.
18. Coiret G., Borowiec A.S., Mariot P., Ouadid-Ahidouch H., Matifat F. The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells. Mol. Pharmacol. 2007, 71:843-851.
19. Visram H., Greer P.A. [20] 17beta-estradiol and tamoxifen stimulate rapid and transient ERK activationin MCF-7 cells via distinct signaling mechanisms. Cancer Biol. Ther. 2006, 5:1677-1682.
20. Chung Y.L., Sheu M.L., Yang S.C., Lin C.H., Yen S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer 2002, 97:306-312.
21. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
22. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 2004, 96:926-935.
23. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol. Endocrinol. 2001, 15:1344-1359.
24. Gee J.M., Robertson J.F., Ellis I.O., Nicholson R.I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 2001, 95:247-254.
25. Pérez-Tenorio G., Stål O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 2002, 86:540-545.
26. Holm C., Rayala S., Jirström K., Stål O., Kumar R., Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl. Cancer Inst. 2006, 98:671-680.
27. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276:9817-9824.
28. Wagner C.A., Finberg K.E., Breton S., Marshansky V., Brown D., Geibel J.P. Renal vacuolar H+-ATPase. Physiol. Rev. 2004, 84:1263-1314.